Mitral valve disease: news from the frontier in valvular heart disease
Key result
Sildenafil 40 mg t.i.d. worsened the composite score compared to placebo (33% vs 15%) in patients with persistent pulmonary hypertension after corrected valvular heart disease.
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This editorial highlights key recent publications in valvular heart disease, emphasizing new diagnostic tools, risk scores, and the importance of guideline adherence.
PICO
P
Population
200 patients with persistent pulmonary hypertension ≥30 mmHg systolic after correction of valvular heart disease.
I
Intervention / Comparator
Sildenafil vs Placebo (40 mg t.i.d.)
O
Primary Outcome
Worsened composite score
Main Result
Absolute Event Rate: 33% vs 15%
This editorial highlights key recent publications in valvular heart disease, emphasizing new diagnostic tools, risk scores, and the importance of guideline adherence.
Cite This Study
Thomas F. Lüscher (2018) conducted an editorial in Persistent pulmonary hypertension after correction of valvular heart disease (n=200). Sildenafil vs. Placebo was evaluated on Worsened composite score. Sildenafil 40 mg t.i.d. worsened the composite score compared to placebo (33% vs 15%) in patients with persistent pulmonary hypertension after corrected valvular heart disease.